» Articles » PMID: 22147713

Association of High-density Lipoprotein Cholesterol with Incident Cardiovascular Events in Women, by Low-density Lipoprotein Cholesterol and Apolipoprotein B100 Levels: a Cohort Study

Overview
Journal Ann Intern Med
Specialty General Medicine
Date 2011 Dec 8
PMID 22147713
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Prior studies have found inverse associations between high-density lipoprotein cholesterol (HDL-C) or apolipoprotein A-I levels and cardiovascular disease (CVD). Whether this observation is consistent across low-density lipoprotein cholesterol (LDL-C) levels or total atherogenic particle burden (apolipoprotein B100) is less well-studied, particularly in women.

Objective: To determine the association between HDL-C or apolipoprotein A-I level and CVD across a range of LDL-C and apolipoprotein B100 values.

Design: Prospective cohort study.

Setting: The Women's Health Study, a cohort of U.S. female health professionals.

Participants: 26,861 initially healthy women, aged 45 years or older at study entry (1992-1995), who were followed for a mean of approximately 11 years.

Measurements: Baseline lipids were measured directly, and apolipoproteins were measured with immunoassays. Outcomes were incident total CVD (n = 929), coronary events (n = 602), and stroke (n = 319).

Results: In multivariable analyses, HDL-C and apolipoprotein A-I levels were inversely associated with CVD and coronary events but not stroke. Adjusted coronary hazard ratios for decreasing quintiles of HDL-C were 1.00 (reference), 1.23 (95% CI, 0.85 to 1.78), 1.42 (CI, 0.98 to 2.06), 1.90 (CI, 1.33 to 2.71), and 2.19 (CI, 1.51 to 3.19) (P for linear trend < 0.001); corresponding hazard ratios for apolipoprotein A-I were 1.00 (reference), 0.98 (CI, 0.71 to 1.35), 1.02 (CI, 0.72 to 1.44), 1.37 (CI, 0.98 to 1.90), and 1.58 (CI, 1.14 to 2.20) (P for linear trend = 0.005). Consistent inverse associations were found for HDL-C with coronary events across a range of LDL-C values, including among women with low LDL-C levels. No associations were noted for HDL-C or apolipoprotein A-I among women with low apolipoprotein B100 values (<0.90 g/L).

Limitation: Participants were at low risk for CVD, the number of events in the lowest apolipoprotein B100 stratum was small, only a single baseline measurement was obtained, and residual confounding may have occurred.

Conclusion: Consistent inverse associations were found for HDL-C with incident coronary events among women with a range of LDL-C values. Among women with low total atherogenic particle burden (apolipoprotein B100 level <0.90 g/L), few events occurred and no associations were seen.

Primary Funding Source: Merck & Co. and the National Heart, Lung, and Blood Institute and National Cancer Institute, National Institutes of Health.

Citing Articles

Plasma Biomarker Profiles for Premature and Nonpremature Coronary Heart Disease in Women.

Dugani S, Moorthy M, Demler O, Li C, Ridker P, Glynn R Clin Chem. 2024; 70(5):768-779.

PMID: 38472127 PMC: 11062763. DOI: 10.1093/clinchem/hvae007.


Discrepant effect of high-density lipoprotein cholesterol on esophageal and gastric cancer risk in a nationwide cohort.

Nam S, Jo J, Jeon S Gastric Cancer. 2024; 27(3):451-460.

PMID: 38416240 DOI: 10.1007/s10120-024-01477-7.


Effects of Tributyrin Supplementation on Liver Fat Deposition, Lipid Levels and Lipid Metabolism-Related Gene Expression in Broiler Chickens.

Gu T, Duan M, Liu J, Chen L, Tian Y, Xu W Genes (Basel). 2022; 13(12).

PMID: 36553486 PMC: 9777756. DOI: 10.3390/genes13122219.


Association of lipid, inflammatory, and metabolic biomarkers with age at onset for incident cardiovascular disease.

Tian X, Chen S, Zuo Y, Zhang Y, Zhang X, Xu Q BMC Med. 2022; 20(1):383.

PMID: 36352412 PMC: 9647925. DOI: 10.1186/s12916-022-02592-x.


Study on influencing factors of anthracycline-induced subclinical cardiotoxicity in DLBCL patients administered (R)-CHOP.

Dong Q, Ou W, Wang M, Jiang T, Weng Y, Zhou X BMC Cancer. 2022; 22(1):988.

PMID: 36115970 PMC: 9482309. DOI: 10.1186/s12885-022-10085-6.


References
1.
Bittner V . Perspectives on dyslipidemia and coronary heart disease in women. J Am Coll Cardiol. 2005; 46(9):1628-35. DOI: 10.1016/j.jacc.2005.05.089. View

2.
Bass K, Newschaffer C, Klag M, Bush T . Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 1993; 153(19):2209-16. View

3.
Gordon T, CASTELLI W, Hjortland M, Kannel W, DAWBER T . High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977; 62(5):707-14. DOI: 10.1016/0002-9343(77)90874-9. View

4.
deGoma E, Leeper N, Heidenreich P . Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol. 2008; 51(1):49-55. DOI: 10.1016/j.jacc.2007.07.086. View

5.
Thompson A, Danesh J . Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med. 2006; 259(5):481-92. DOI: 10.1111/j.1365-2796.2006.01644.x. View